News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

CMS accepts Epigenomics’ application for NCD review

PDF Berlin (Germany) and San Diego, CA (U.S.A.), May 3, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company’s application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. The […]

Read more

Epigenomics AG Reports Results for Financial Year 2018

PDF Berlin (Germany) und San Diego, CA (U.S.A.), March 27, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS) for the year ended December 31, 2018. KEY HIGHLIGHTS Financial – Total revenue of EUR 1.5 million and EBITDA (before share-based payment expenses) of EUR -11.4 million (compared […]

Read more

U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill

PDF Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests Berlin (Germany) and San Diego, CA (U.S.A.), March 15, 2019 – Representatives Donald Payne, Jr (D-NJ) and Kenny Marchant (R-TX) today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act” (HR 1765) to the United States House […]

Read more

Epigenomics AG Announces Positive Results from Microsimulation Model

PDF Berlin (Germany) and San Diego, CA (U.S.A.), January 7, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced that a microsimulation model has been completed by external academic experts demonstrating positive results for the Epi proColon® blood test. The manuscript is being finalized and will be submitted for publication soon. Epigenomics will discuss […]

Read more

Epigenomics AG Announces Initiation of a Prospective Clinical Study for Liver Cancer Detection

PDF Berlin (Germany) and San Diego, CA (U.S.A.), 20 December, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced the initiation of a multi-center validation and development study of its methylated cell free DNA biomarkers to aid in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. As an expansion of its molecular […]

Read more

Centers for Medicare & Medicaid Services issue official 2019 Clinical Lab Fee Schedule including Epi proColon®

PDF Berlin (Germany) and San Diego, CA (U.S.A.), December 19, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) have issued its official 2019 Clinical Lab Fee Schedule (CLFS) on December 14, 2018, including the final reimbursement rate of $192 for Epi proColon®, […]

Read more